ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES

被引：0
|
作者：
Prajapatil, Vimal [1 ,2 ,3 ,4 ,5 ,6 ]
Simpson, Eric L. [7 ]
Thyssen, Jacob P. [8 ]
Chovatiya, Raj [9 ]
Lane, Michael [10 ]
Teixeira, Henrique [10 ]
Calimlim, Brian [10 ]
Silverberg, Jonathan I. [11 ]
机构：
[1] Univ Calgary, Div Dermatol, Dept Med, Calgary, AB, Canada
[2] Univ Calgary, Sect Community Pediat, Dept Pediat, Calgary, AB, Canada
[3] Univ Calgary, Sect Pediat Rheumatol, Dept Pediat, Calgary, AB, Canada
[4] Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[5] Dermatol Res Inst, Calgary, AB, Canada
[6] Prob Med Res, Calgary, AB, Canada
[7] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[8] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
[9] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA
[10] AbbVie Inc, N Chicago, IL USA
[11] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P4.17
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [31] Depth of response to abrocitinib in adults with moderate-to-severe atopic dermatitis (AD): Pooled analysis of monotherapy studies
    Staender, Sonja
    Bhatia, Neal
    Gooderham, Melinda J.
    Silverberg, Jonathan I.
    Thyssen, Jacob P.
    Biswas, Pinaki
    DiBonaventura, Marco
    Romero, William
    Farooqui, Saleem A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB148 - AB148
  • [32] Interpretation of EASI-75 from a patient perspective - a post-hoc analysis from a phase 2b trial of dupilumab in adults with moderate-to-severe atopic dermatitis
    Poulin, Y.
    Tyring, S.
    Kimura, T.
    Andria, M.
    Ghorayeb, E.
    Eckert, L.
    Chao, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 142 - 142
  • [33] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    de Bruin-Weller, Marjolein S.
    Papp, Kim A.
    Aoki, Valeria
    Paller, Amy S.
    Ofori, Sarah
    Tenorio, Allan R.
    Liu, Yingyi
    Liu, Jianzhong
    Chovatiya, Raj
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
  • [34] UPADACITINIB VERSUS DUPILUMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF THE HEADS UP PHASE 3 TRIAL
    Blauvelt, Andrew
    Teixeira, Henrique D.
    Simpson, Eric L.
    Costanzo, Antonio
    De Bruin-Weller, Marjolein
    Barbarot, Sebastien
    Prajapati, Vimal H.
    Lio, Peter
    Hu, Xiaofei
    Wu, Tianshuang
    Liu, John
    Ladizinski, Barry
    Chu, Alvina D.
    Eyerich, Kilian
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 62 - 62
  • [35] Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (S<underline>EASI</underline>DE CHINA)
    Zhang, Jianzhong
    Silverberg, Jonathan, I
    Guo, Jiawang
    Yun, Jili
    Pan, Wuban
    Wei, Zheng
    Collazo, Raul
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [36] EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Cork, Michael J.
    Paller, Amy S.
    Siegfried, Elaine C.
    Xiao, Jing
    Prescilla, Randy
    Dubost-Brama, Ariane
    Bansal, Ashish
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
  • [37] DUPILUMAB TREATMENT REDUCES HOSPITALIZATIONS IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A POOLED ANALYSIS OF DATA FROM 7 RANDOMIZED, PLACEBO-CONTROLLED STUDIES
    Silverberg, J.
    Rubini, N.
    Pires, M. C.
    Rossi, A.
    Zhang, A.
    Chen, Z.
    Levit, N. A.
    Thomas, R.
    Shumel, B.
    Bego, G.
    VALUE IN HEALTH, 2022, 25 (01) : S20 - S20
  • [38] Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis: a pooled analysis of data from seven randomized, placebo-controlled studies
    Rubini, N. P. M.
    Silverberg, J. I.
    Pires, M. C.
    Chen, Z.
    Chao, J.
    Bego-Le Bagousse, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E116 - E117
  • [39] Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from two pivotal, phase III, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)
    Guttman-Yassky, E.
    Teixeira, H. D.
    Simpson, E. L.
    Papp, K. A.
    Pangan, A. L.
    Blauvelt, A.
    Thaci, D.
    Chu, C. Y.
    Hong, H. C.
    Katoh, N.
    Paller, A. S.
    Calimlim, B.
    Gu, Y.
    Hu, X.
    Liu, M.
    Yang, Y.
    Tenorio, A. R.
    Chu, A. D.
    Irvine, A. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E62 - E62
  • [40] An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis
    Werfel, T.
    Irvine, A. D.
    Bangert, C.
    Seneschal, J.
    Grond, S.
    Cardillo, T.
    Brinker, D.
    Zhong, J.
    Riedl, E.
    Wollenberg, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (09) : 1486 - 1496
12345